News Website

Endometrial Cancer: Evaluating Platinum Re-Challenge Strategies Through the ECHO-EU Lens - OncLive

Endometrial Cancer: Evaluating Platinum Re-Challenge Strategies Through the ECHO-EU Lens OncLive

Published: Jan. 9, 2026, 8:25 p.m.

Read Full Article

Endometrial Cancer: Future Directions - Biomarkers, Sequencing, and Survivorship Priorities - OncLive

Endometrial Cancer: Future Directions - Biomarkers, Sequencing, and Survivorship Priorities OncLive

Published: Jan. 9, 2026, 2:17 p.m.

Read Full Article

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.

Read Full Article

The role of insulin-like growth factor binding proteins in TGF-β1-induced fibroblast-myofibroblast transition during endometriosis fibrosis.

Fibrosis is a defining feature of endometriosis (EMS). Our previous single-cell RNA sequencing (scRNA-seq) revealed myofibroblasts (MFBs) as the predominant cells in ectopic endometrium (ECE), mainly derived from fibroblast-to-myofibroblast transition …

Published: Jan. 9, 2026, midnight

Read Full Article

Endometriosis Fibroblast-to-myofibroblast transition Fibrosis IGFBP TGF-β

Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq

Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data Nasdaq

Published: Jan. 8, 2026, 7:14 p.m.

Read Full Article

Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks

Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating TipRanks

Published: Jan. 8, 2026, 7:11 p.m.

Read Full Article

Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq

Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe Nasdaq

Published: Jan. 8, 2026, 1:42 p.m.

Read Full Article

Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Australia

Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com Investing.com Australia

Published: Jan. 8, 2026, 1:10 p.m.

Read Full Article

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks

Published: Jan. 8, 2026, 1:01 p.m.

Read Full Article

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.

Read Full Article

Latest Articles

Endometrial Cancer: Evaluating Platinum Re-Challenge Strategies Through the ECHO-EU Lens - OncLive

Endometrial Cancer: Future Directions - Biomarkers, Sequencing, and Survivorship Priorities - OncLive

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

The role of insulin-like growth factor binding proteins in TGF-β1-induced fibroblast-myofibroblast transition during endometriosis fibrosis.

Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq

Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks

Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq

Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Australia

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Subscribe to Our Newsletter